Medicare Coverage for Multiple Sclerosis: 2025 Guide
Multiple sclerosis affects approximately 1 million Americans. While MS is often diagnosed in younger adults (20s–50s), many patients reach Medicare age while still managing the disease — and some younger patients qualify for Medicare through Social Security Disability Insurance (SSDI) after 24 months of receiving disability benefits. MS disease-modifying therapies are among the most expensive drugs in all of medicine, making the 2025 Part D $2,000 out-of-pocket cap one of the most financially significant changes for MS patients in Medicare history.
Multiple Sclerosis Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| Neurologist visits (MS specialist) | Part B | 20% after $257 deductible | MS center or movement disorder neurologist recommended |
| Brain/spinal cord MRI | Part B | 20% after deductible | Essential for diagnosis and monitoring disease activity |
| Lumbar puncture (spinal tap) | Part B | 20% after deductible | For diagnosis (oligoclonal bands, IgG index) |
| Visual evoked potentials | Part B | 20% after deductible | Optic nerve function testing for diagnosis |
| IV methylprednisolone (relapse treatment) | Part B | 20% after deductible | High-dose steroid; physician-administered infusion |
| Natalizumab (Tysabri) — IV infusion | Part B | 20% after deductible | Monthly infusion; physician-administered; Part B |
| Ocrelizumab (Ocrevus) — IV infusion | Part B | 20% after deductible | Every 6 months; covers RRMS and primary progressive MS |
| Ofatumumab (Kesimpta) — SC self-injection | Part D | Up to $2,000 OOP cap | Monthly self-injection; Part D coverage |
| Interferon beta (Avonex, Rebif, Betaseron, Plegridy) | Part D | Up to $2,000 OOP cap | Self-injected; Part D coverage |
| Glatiramer (Copaxone, Glatopa) | Part D | Up to $2,000 OOP cap | Self-injected; generic glatiramer available |
| Oral DMTs (Tecfidera, Aubagio, Mayzent, Zeposia, Vumerity) | Part D | Up to $2,000 OOP cap | Oral disease-modifying therapies; Part D coverage |
| Cladribine (Mavenclad) | Part D | Up to $2,000 OOP cap | Oral; short-course high-efficacy therapy |
| Ozanimod (Zeposia) | Part D | Up to $2,000 OOP cap | Oral S1P modulator |
| Baclofen (oral or intrathecal pump) | Part D (oral); Part B (pump) | Tier 1 (oral); 20% (pump) | Spasticity management; pump surgery covered under Part A |
| Dalfampridine (Ampyra) | Part D | Tier 3–4; OOP cap applies | Improves walking speed in MS patients |
| Physical therapy | Part B | 20% after deductible | Gait, balance, strength, fatigue management; no annual cap |
| Occupational therapy | Part B | 20% after deductible | ADL training, adaptive equipment, energy conservation |
| Speech-language pathology | Part B | 20% after deductible | Dysarthria, cognitive-communication, dysphagia |
| Botulinum toxin (Botox) for spasticity | Part B | 20% after deductible | Physician-administered; Part B coverage |
| Home health (skilled) | Part A/B | $0 for covered services | When homebound; PT, OT, skilled nursing |
| Power wheelchair / scooter | Part B (DME) | 20% after deductible | When ambulation severely limited; requires documentation |
| Urinary catheter supplies | Part B (DME) | 20% after deductible | For neurogenic bladder; covered as medical supplies |
How Younger MS Patients Get Medicare
MS is commonly diagnosed in people ages 20–50, well before Medicare eligibility age. Younger adults with MS can qualify for Medicare through disability:
- Apply for Social Security Disability Insurance (SSDI) based on MS disability
- After approval, receive SSDI benefits for 24 months
- Medicare coverage begins automatically at month 25
This means a person diagnosed with disabling MS at age 35 could be on Medicare by age 37–38. For these patients, navigating Medicare's coverage rules — particularly the Part B vs. Part D distinction for MS drugs — is critical knowledge.
The Most Important MS Coverage Decision: Part B vs. Part D Drugs
Which part of Medicare covers your MS drug determines your cost structure — and your Medigap strategy:
Infused MS Drugs → Part B (Physician-Administered)
If your MS drug is given by IV infusion in a clinic or infusion center, it's covered under Part B:
- Ocrelizumab (Ocrevus): Every 6 months; covers relapsing and primary progressive MS
- Natalizumab (Tysabri): Monthly infusions
- Ublituximab (Briumvi): Every 6 months
- IV methylprednisolone: For acute relapses
You pay 20% coinsurance. For Ocrevus (approximately $80,000/year), 20% = $16,000/year without Medigap. Medigap Plan G covers the entire 20%, making these infusions effectively free after the Part B deductible. For patients on high-efficacy infused therapies, Medigap Plan G is essentially mandatory.
Self-Injected and Oral MS Drugs → Part D
Self-injected interferons, glatiramer, ofatumumab, and all oral MS drugs are covered under Part D. These are uniformly expensive brand-name medications. Before 2025, MS patients on Part D could spend $5,000–$8,000+ in annual drug costs. The 2025 $2,000 OOP cap changes this substantially.
Choosing Between Medigap and Medicare Advantage for MS
For MS patients, Original Medicare + Medigap Plan G is almost always the superior choice:
- Medigap Plan G eliminates 20% coinsurance on infused biologics — potentially saving $10,000–$16,000/year
- Original Medicare has no network restrictions — critical for MS patients who need MS center specialists that may not be in MA networks
- Medicare Advantage plans frequently require prior authorization and step therapy for high-cost MS drugs
- MA plans may deny or delay coverage for newer high-efficacy therapies
The annual Medigap Plan G premium (typically $1,500–$3,000/year depending on age and location) is far outweighed by the savings on infused MS drug coinsurance alone.
Rehabilitation Therapies: Essential and Covered
Physical, occupational, and speech therapy play important roles across all stages of MS. Medicare covers all three under Part B with no hard annual cap:
- Physical therapy: Gait and balance training, fatigue management, aerobic conditioning, spasticity management
- Occupational therapy: Energy conservation techniques, adaptive equipment, home modification planning, fine motor training
- Speech-language pathology: Dysarthria (slurred speech), cognitive-communication issues, and dysphagia
Telehealth therapy visits are covered — particularly valuable for MS patients with mobility limitations or fatigue who find in-person visits difficult.
Spasticity Treatment
Spasticity affects up to 80% of MS patients. Medicare covers multiple treatment approaches:
- Oral baclofen: Part D, Tier 1 generic — very inexpensive
- Tizanidine: Part D, Tier 1 generic — inexpensive
- Botulinum toxin (Botox) injections: Part B — physician-administered; 20% coinsurance
- Intrathecal baclofen pump: Pump implantation surgery under Part A; ongoing refills and management under Part B
Frequently Asked Questions
Yes. Ocrevus (ocrelizumab) is covered under Medicare Part B because it is administered by IV infusion in a physician's office or infusion center. You pay 20% of the Medicare-approved amount. At Ocrevus's list price (~$80,000/year), 20% equals approximately $16,000/year — which is why Medigap Plan G is essentially essential for patients on Ocrevus. Medigap Plan G covers that 20% entirely, making Ocrevus infusions free after the annual $257 Part B deductible.
Yes. Oral MS disease-modifying therapies — including dimethyl fumarate (Tecfidera, Vumerity), teriflunomide (Aubagio), siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvory), and cladribine (Mavenclad) — are covered under Medicare Part D. These drugs cost $70,000–$100,000/year at list price. Starting in 2025, the Part D out-of-pocket cap is $2,000/year — meaning your maximum annual drug spending is $2,000 regardless of the drug's cost. Compare Part D plans during Annual Election Period for the best formulary placement.
Yes. If your MS causes disability that prevents you from working, you may qualify for Social Security Disability Insurance (SSDI). After receiving SSDI for 24 months, Medicare coverage begins automatically — regardless of your age. This is how many younger MS patients access Medicare. The 24-month waiting period is a significant gap; during this period, many patients rely on employer coverage, marketplace insurance, or Medicaid. Once Medicare begins, you can enroll in Medigap and Part D for comprehensive coverage.